Gilead Sciences Inc. (GILD)
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead’s portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Gilead Sciences Inc. (GILD)’s Financial Overview
Gilead Sciences Inc. (GILD) surged 0.9% yesterday to close its trading session at $74.78. The company has 1 year Price Target of $88.91. The stock touched its 52-Week High on Obsolete and 52-Week Low on Obsolete. The stock traded with the volume of 6.49 Million shares yesterday. The firm shows the market capitalization of $101.63 Billion.
Gilead Sciences Inc. (GILD) reported its last quarterly earnings on 12/30/2017 where the firm reported its Actual EPS of $1.78/share. The difference between the actual and expected EPS is $0.11 a share with a surprise factor of 6.6%.
The firm is trading with SMA20 of -4.42 Percent, SMA50 of SMA50 Percent and SMA200 of -2.37 percent. Gilead Sciences Inc. has P/S value of 3.89 while its P/B value stands at 4.78. Similarly, the company has Return on Assets of 7.3 percent, Return on Equity of 20.9 percent and Return on Investment of 19.9 Percent. The company shows Gross Margin and Operating Margin of 83.3 percent and 54.1 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2.2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 22 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 87.00, with a high estimate of 103.00 and a low estimate of 65.00. The median estimate represents a +16.34% increase from the last price of 74.78.
The Bank of New York Mellon Corporation (BK)
Bank of New York Mellon Corporation (BNY Mellon) is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. Whether providing financial services for institutions, corporations or individual investors, BNY Mellon delivers informed investment management and investment services in 35 countries and more than 100 markets. BNY Mellon can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute or restructure investments. Over the years, BNY Mellon has maintained a valued presence in Asia Pacific, where they have been one of the first U.S. financial institutions to invest in the region’s vast potential. They have over 12,000 employees in the region and maintain extensive operations in 16 locations.
The Bank of New York Mellon Corporation (BK)‘s Financial Outlook
The 20 analysts offering 12-month price forecasts for Bank of New York Mellon Corp have a median target of 60.00, with a high estimate of 66.00 and a low estimate of 54.00. The median estimate represents a +18.55% increase from the last price of 50.61.
According to Zacks Investment Research, The Bank of New York Mellon Corporation has a Consensus Recommendation of 2.27. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock declined-0.22% and closed its last trading session at $50.61. The company has the market capitalization of $53.14 Billion. The firm touched its 52-Week high on Obsolete and 52-Week low on Obsolete. The company has volume of 6.5 Million shares. The company has a total of 1.05 Billion shares outstanding.
The company has YTD performance of -6.03 percent. Beta for The Bank of New York Mellon Corporation stands at 1.2 while its ATR (average true range) is 1.39. The company has Weekly Volatility of 3.48%% and Monthly Volatility of 2.62%.
The Bank of New York Mellon Corporation has distance from 20-day Simple Moving Average (SMA20) of -7.74%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of -5.41%.
The Company currently has ROA (Return on Assets) of 1.1 percent, Return on Equity (ROE) of 10.6 Percent and Return on Investment (ROI) of 3.2% and Operating & Profit margin of 76% and 88.4% respectively.